» Articles » PMID: 38802667

Virus-like Structures for Combination Antigen Protein MRNA Vaccination

Abstract

Improved vaccination requires better delivery of antigens and activation of the natural immune response. Here we report a lipid nanoparticle system with the capacity to carry antigens, including mRNA and proteins, which is formed into a virus-like structure by surface decoration with spike proteins, demonstrating application against SARS-CoV-2 variants. The strategy uses S1 protein from Omicron BA.1 on the surface to deliver mRNA of S1 protein from XBB.1. The virus-like particle enables specific augmentation of mRNAs expressed in human respiratory epithelial cells and macrophages via the interaction the surface S1 protein with ACE2 or DC-SIGN receptors. Activation of macrophages and dendritic cells is demonstrated by the same receptor binding. The combination of protein and mRNA increases the antibody response in BALB/c mice compared with mRNA and protein vaccines alone. Our exploration of the mechanism of this robust immunity suggests it might involve cross-presentation to diverse subsets of dendritic cells ranging from activated innate immune signals to adaptive immune signals.

Citing Articles

The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.

Zhang J, Zeng F, Li Y, Mu C, Liu C, Wang L Hum Vaccin Immunother. 2025; 21(1):2473183.

PMID: 40045463 PMC: 11901403. DOI: 10.1080/21645515.2025.2473183.


Review on the bioanalysis of non-virus-based gene therapeutics.

Zhou M, Zhang X, Yan H, Xing L, Tao Y, Shen L Bioanalysis. 2024; 16(23-24):1279-1294.

PMID: 39673530 PMC: 11703353. DOI: 10.1080/17576180.2024.2437418.


Mannose/stearyl chloride doubly functionalized polyethylenimine as a nucleic acid vaccine carrier to promote macrophage uptake.

Bai L, Chen X, Li C, Zhou H, Li Y, Xiao J Drug Deliv. 2024; 31(1):2427138.

PMID: 39540234 PMC: 11565675. DOI: 10.1080/10717544.2024.2427138.


Virus-like structures for combination antigen protein mRNA vaccination.

Zhang J, Li Y, Zeng F, Mu C, Liu C, Wang L Nat Nanotechnol. 2024; 19(8):1224-1233.

PMID: 38802667 PMC: 11329372. DOI: 10.1038/s41565-024-01679-1.

References
1.
Chang T, Yang J, Deng H, Chen D, Yang X, Tang Z . Depletion and Dysfunction of Dendritic Cells: Understanding SARS-CoV-2 Infection. Front Immunol. 2022; 13:843342. PMC: 8898834. DOI: 10.3389/fimmu.2022.843342. View

2.
Zhang J, Li Y, Zeng F, Mu C, Liu C, Wang L . Virus-like structures for combination antigen protein mRNA vaccination. Nat Nanotechnol. 2024; 19(8):1224-1233. PMC: 11329372. DOI: 10.1038/s41565-024-01679-1. View

3.
Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igyarto B . The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021; 24(12):103479. PMC: 8604799. DOI: 10.1016/j.isci.2021.103479. View

4.
Huyser K, Yellow Horse A, Kuhlemeier A, Huyser M . COVID-19 Pandemic and Indigenous Representation in Public Health Data. Am J Public Health. 2021; 111(S3):S208-S214. PMC: 8561074. DOI: 10.2105/AJPH.2021.306415. View

5.
Eygeris Y, Gupta M, Kim J, Sahay G . Chemistry of Lipid Nanoparticles for RNA Delivery. Acc Chem Res. 2021; 55(1):2-12. DOI: 10.1021/acs.accounts.1c00544. View